Benevolent AI and AstraZeneca expand collaboration on heart failure and systemic lupus discovery

Leading clinical stage AI drug discovery company, Benevolent AI, has expanded its AI-driven drug discovery collaboration with AstraZeneca. This means that the number of disease areas being explored through the partnership will be doubled.

The expansion builds on the partnership initiated in 2019, and adds systemic lupus erythematosus (SLE) and heart failure (HF) to research on identifying multiple novel targets in chronic kidney disease (CKD) and idiopathic pulmonary fibrosis (IPF).

read more